ASH Highlights and Commentary: Lymphoid Malignancies

Viviana Perez, APRN, FNP-C, of Moffitt Cancer Center, considers findings presented at the 2024 ASH Annual Meeting on bispecific antibodies for DLBCL and the efficacy of CAR T-cell therapy. Laura Zitella, MS, RN, ACNP-BC, AOCN, of UCSF, evaluates studies on omitting transplant in MCL, CD19-directed monoclonal antibodies in FL, and the duration of lenalidomide maintenance in MM.